XZB(SH:603040) Zheng Quan Shi Bao Wang·2025-06-30 09:26Core Insights - The biopharmaceutical industry in China has significant growth potential, driven by a series of supportive policies aimed at promoting innovative drug development [1][2] - Companies in the Shenzhen market are focusing on independent innovation to explore new frontiers in life and health, contributing to the global pharmaceutical innovation landscape [1][2] Policy Support - The Chinese government has intensified support for the innovative drug industry, with a comprehensive policy framework established in July 2024 to enhance various aspects such as pricing management, insurance payments, and clinical trial approvals [2] - Local governments are also actively promoting the development of innovative drugs, exemplified by Beijing's plan for high-quality construction of an international pharmaceutical innovation park from 2025 to 2030 [2] Company Developments - Huadong Medicine (000963) has 133 ongoing pharmaceutical projects, with 94 focused on innovative drugs and biosimilars, including a diverse range of drug types targeting various diseases [3][5] - Haizhu Pharmaceutical (002653) has 14 innovative drug products in clinical stages, emphasizing its commitment to becoming a trusted international pharmaceutical company [3] - Betta Pharmaceuticals (300558) has over 20 years of experience in cancer drug innovation and is focused on developing proprietary drugs [3] Financial Performance - Huadong Medicine reported a 16.77% increase in R&D investment to 2.678 billion yuan in 2024, with direct R&D expenses accounting for 12.91% of its pharmaceutical revenue [5][6] - Haizhu Pharmaceutical's revenue reached 3.721 billion yuan in 2024, a 10.92% increase, with a net profit of 395 million yuan, reflecting a 34% growth [6] - Betta Pharmaceuticals achieved a revenue of 2.892 billion yuan in 2024, marking a 17.74% increase, with a net profit growth of 55.92% [7]